Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AeroVax: Phase 2 Trial of Inhaled COVID-19 Vaccine
NCT06381739Phase 2Recruiting
- Sponsor
- McMaster University
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ChAd-triCoV/Mac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by McMaster University. Primary endpoints: Antigen specific T cell responses in blood at 2 weeks, Antigen specific T cell responses in bronchoalveolar lavage (BAL) at 4 weeks and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
ChAd-triCoV/Mac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06381739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381739.